Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele.
OBJECTIVE
To investigate with fluorodeoxyglucose positron emission tomography whether regional reductions in the cerebral metabolic rate for glucose (CMRgl) previously found in cognitively healthy late-middle-aged apolipoprotein E (APOE) epsilon4 carriers extend to members of the Latino Mexican American community.


METHODS
Prospective cohort study.


METHODS
Banner Alzheimer's Institute, Phoenix, Arizona.


METHODS
Eleven APOE epsilon4 carriers and 16 noncarriers from Arizona's Latino community (mean [SD] age, 54.6 [6.4] years) matched for sex, mean age, and educational level and who were predominantly of self-designated Mexican origin.


METHODS
A brain mapping algorithm was used to compare cross-sectional regional CMRgl in Latino APOE epsilon4 carriers vs noncarriers.


RESULTS
Participant groups had similar distributions for age, sex, education, family history of dementia, clinical ratings, and neuropsychological test scores. Latino APOE epsilon4 carriers had lower CMRgl than the noncarriers in the posterior cingulate, precuneus, and parietal regions previously found to be preferentially affected in patients with Alzheimer disease (AD) and cognitively healthy non-Latino APOE epsilon4 carriers. Additionally, the Latino APOE epsilon4 carriers had lower CMRgl in the middle and anterior cingulate cortex, hippocampus, and thalamus.


CONCLUSIONS
This study provides support for the relationship between APOE epsilon4 and risk of AD in Latino individuals. It illustrates the role of positron emission tomography as a presymptomatic endophenotype for the assessment of AD risk factors and supports the inclusion of Latino APOE epsilon4 carriers in proof-of-concept studies using fluorodeoxyglucose PET to evaluate promising presymptomatic treatments in cognitively healthy carriers of this common AD susceptibility gene.
Langbaum
Jessica B S
JB
Banner Alzheimer's Institute, 901 E Willetta St, Phoenix, AZ 85006, USA. jessica.langbaum@bannerhealth.com
Chen
Kewei
K
Caselli
Richard J
RJ
Lee
Wendy
W
Reschke
Cole
C
Bandy
Daniel
D
Alexander
Gene E
GE
Burns
Christine M
CM
Kaszniak
Alfred W
AW
Reeder
Stephanie A
SA
Corneveaux
Jason J
JJ
Allen
April N
AN
Pruzin
Jeremy
J
Huentelman
Matthew J
MJ
Fleisher
Adam S
AS
Reiman
Eric M
EM
D000368:Aged; D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000235:genetics* / Q000378:metabolism*; D053327:Apolipoprotein E4 / Q000235:genetics*; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000503:physiopathology; D001928:Brain Diseases, Metabolic / Q000000981:diagnostic imaging / Q000235:genetics* / Q000378:metabolism*; D001931:Brain Mapping / Q000379:methods; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D004252:DNA Mutational Analysis; D005260:Female; D019788:Fluorodeoxyglucose F18; D005787:Gene Frequency / Q000235:genetics; D006580:Genetic Carrier Screening; D005819:Genetic Markers / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000235:genetics; D005820:Genetic Testing; D005838:Genotype; D006579:Heterozygote; D006630:Hispanic or Latino / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011446:Prospective Studies; D012307:Risk Factors
D053327:Apolipoprotein E4; D005819:Genetic Markers; D019788:Fluorodeoxyglucose F18
Arch Neurol. 2007 Apr;64(4):501-6
17420311
J Nucl Med. 2008 Mar;49(3):390-8
18287270
Arch Neurol. 2002 Jan;59(1):87-91
11790235
JAMA. 1995 Mar 22-29;273(12):942-7
7884953
Am J Hum Genet. 1996 Mar;58(3):574-84
8644717
Am J Psychiatry. 2002 May;159(5):738-45
11986126
Alzheimer Dis Assoc Disord. 2002 Jan-Mar;16(1):8-14
11882744
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):284-9
14688411
Neuroimage. 2009 Aug 15;47(2):602-10
19393744
J Neurosci. 2006 May 31;26(22):6069-76
16738250
J Psychiatr Res. 1975 Nov;12(3):189-98
1202204
Nat Genet. 2008 Oct;40(10):1166-74
18776908
JAMA. 1997 Oct 22-29;278(16):1349-56
9343467
Arch Neurol. 2004 Sep;61(9):1434-9
15364690
Arch Neurol. 2006 Nov;63(11):1586-90
17101827
Arch Neurol. 2005 May;62(5):774-8
15883265
Science. 1988 Apr 29;240(4852):622-30
3283935
JAMA. 1998 Mar 11;279(10):751-5
9508150
Ann Neurol. 1984;15 Suppl:S170-4
6611118
Ann Neurol. 1984 Dec;16(6):649-54
6335378
Ann Neurol. 1995 Sep;38(3):463-5
7668835
N Engl J Med. 2009 Jul 16;361(3):255-63
19605830
Science. 1993 Aug 13;261(5123):921-3
8346443
N Engl J Med. 1996 Mar 21;334(12):752-8
8592548
Arch Neurol. 2003 Aug;60(8):1119-22
12925369
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3334-9
11248079
JAMA. 1989 Nov 10;262(18):2551-6
2810583
Int Psychogeriatr. 2004 Sep;16(3):317-26
15559755
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
14399272
Neurology. 2009 Feb 10;72(6):513-20
19005175
J Nucl Med. 1995 Jul;36(7):1238-48
7790950
JAMA. 2001 Nov 7;286(17):2120-7
11694153
Ann Neurol. 1995 Feb;37(2):254-9
7847867
Arterioscler Thromb Vasc Biol. 1996 Sep;16(9):1184-8
8792773
J Alzheimers Dis. 2008 Mar;13(2):137-46
18376055
Neurology. 2008 Nov 4;71(19):1489-95
18981370
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8299-302
15932949
Ann Neurol. 1993 Nov;34(5):752-4
8239575
Neurosci Lett. 2001 Jun 8;305(2):135-8
11376902
J Neurosci Methods. 1994 Aug;53(2):125-7
7823614
Neuroimage. 2009 May 1;45(4):1107-16
19349228
Hum Genet. 1993 May;91(4):326-32
8500788
Am J Hum Genet. 2007 Sep;81(3):559-75
17701901
Am J Geriatr Psychiatry. 2000 Summer;8(3):254-6
10910426
Diabetes. 1991 Mar;40(3):334-7
1999275
Brain. 2009 Feb;132(Pt 2):383-91
18829694
Neurology. 2001 Jan 9;56(1):49-56
11148235
Neurology. 1988 Jun;38(6):909-12
3259296
Ann Neurol. 1995 Jan;37(1):118-20
7818244